Mr. Qingxian Kong joined Chengdu New Radiomedicine Technology Co., Ltd. in 2023 and is the Chief Medical Officer. Mr. Kong is a PhD in Medical Oncology from Roswell Park Cancer Center in the United States and received his bachelor's degree from Shanghai Medical College of Fudan University. Mr. Kong was the radiotherapist at Fudan Cancer Hospital in Shanghai, Medical Affairs Manager at Schering-Plough, Research Team Leader at Roche Clinical Programs, Medical Director at Bayer (hematological malignancies), Senior Medical Director at SUNKI, Head of Global Medical Affairs at Novartis for ribociclib (CDK4/6 inhibitor) and alpelisib (α-PI3K inhibitor) in breast cancer, Vice President of clinical oncology at Jiangsu Hengrui Pharmaceutical Co., Ltd., Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, and Chief Medical Officer of Reindeer Medical.

Dr. Kong has years of experience as radiotherapist, more than 20 years in medical-related work and management experience with multinational pharmaceutical companies. He is familiar with regulatory strategies of China CDE (Center for Drug Evaluation, NMPA) and U.S. FDA, and is familiar with the status quo of global novel drug development. Dr. Kong has rich experience in the fields of oncology, immunology, hematology, etc. as well as the clinical development of innovative and biosimilar drugs around the world.